Eli Lilly and Company (NYSE:LLY) Shares Sold by Montag A & Associates Inc.

Montag A & Associates Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.9% in the third quarter, Holdings Channel reports. The firm owned 29,858 shares of the company’s stock after selling 586 shares during the period. Eli Lilly and Company makes up about 1.0% of Montag A & Associates Inc.’s investment portfolio, making the stock its 20th biggest position. Montag A & Associates Inc.’s holdings in Eli Lilly and Company were worth $16,038,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. State Street Corp increased its position in Eli Lilly and Company by 1.9% in the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after buying an additional 642,274 shares during the period. Geode Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 2.3% during the second quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock valued at $7,111,568,000 after acquiring an additional 338,077 shares during the period. Morgan Stanley grew its position in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares in the last quarter. Norges Bank bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $3,416,206,000. Finally, Capital Research Global Investors grew its position in Eli Lilly and Company by 10.7% in the second quarter. Capital Research Global Investors now owns 6,782,977 shares of the company’s stock worth $3,181,061,000 after acquiring an additional 654,026 shares in the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Citigroup lifted their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. UBS Group restated a “buy” rating and issued a $710.00 price target (up from $612.00) on shares of Eli Lilly and Company in a research note on Friday, October 20th. TheStreet cut Eli Lilly and Company from a “b” rating to a “c+” rating in a report on Monday, December 4th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $621.81.

Read Our Latest Stock Report on LLY

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 195,055 shares of company stock worth $125,254,657. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $6.19 during trading on Monday, hitting $733.97. 2,165,256 shares of the company’s stock were exchanged, compared to its average volume of 3,402,683. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $745.70. The business’s 50-day simple moving average is $620.02 and its 200 day simple moving average is $581.92. The company has a market cap of $696.77 billion, a price-to-earnings ratio of 127.61, a PEG ratio of 2.08 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the company earned $2.09 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.71%. Eli Lilly and Company’s dividend payout ratio is presently 77.93%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.